A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Clinical trial NCT06163326 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06163326
- Sponsor
- Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-19
- Primary completion
- 2027-03-31
- Enrollment
- 394
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.